4D Pharma is preparing to move its irritable bowel syndrome drug, Blautix, into a phase II clinical trial, The Press and Journal reports.
Here's what you should know:
1. Blautix completed a phase I trial last year, showing it was both safe and well tolerated by patients.
2. 4D Pharma researchers said their research claims the microbiome causes or exacerbates IBS.
3. Blautix uses live bacteria to treat irritable bowel syndrome by reacting with bacteria present in the microbiome.